| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLT25D2 |
| Uniprot No | Q8IYK4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-626aa |
| 氨基酸序列 | RFV AERDSEDDGE EPVVFPESPL QSPTVLVAVL ARNAAHTLPH FLGCLERLDY PKSRMAIWAA TDHNVDNTTE IFREWLKNVQ RLYHYVEWRP MDEPESYPDE IGPKHWPTSR FAHVMKLRQA ALRTAREKWS DYILFIDVDN FLTNPQTLNL LIAENKTIVA PMLESRGLYS NFWCGITPKG FYKRTPDYVQ IREWKRTGCF PVPMVHSTFL IDLRKEASDK LTFYPPHQDY TWTFDDIIVF AFSSRQAGIQ MYLCNREHYG YLPIPLKPHQ TLQEDIENLI HVQIEAMIDR PPMEPSQYVS VVPKYPDKMG FDEIFMINLK RRKDRRDRML RTLYEQEIEV KIVEAVDGKA LNTSQLKALN IEMLPGYRDP YSSRPLTRGE IGCFLSHYSV WKEVIDRELE KTLVIEDDVR FEHQFKKKLM KLMDNIDQAQ LDWELIYIGR KRMQVKEPEK AVPNVANLVE ADYSYWTLGY VISLEGAQKL VGANPFGKML PVDEFLPVMY NKHPVAEYKE YYESRDLKAF SAEPLLIYPT HYTGQPGYLS DTETSTIWDN ETVATDWDRT HAWKSRKQSR IYSNAKNTEA LPPPTSLDTV PSRDEL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于重组蛋白研究领域模拟生成的3篇示例文献(注：由于“LT25D2”名称可能存在拼写误差，以下内容为假设性参考结构)：
1. **文献名称**：《人源重组LTB4D2蛋白的高效表达及酶活性分析》
**作者**：李明等
**摘要**：本研究通过优化密码子，在大肠杆菌系统中成功表达可溶性重组人LTB4D2蛋白，经镍柱纯化后获得高纯度产物。酶活实验表明该蛋白对白三烯B4具有特异性羟基脱氢酶活性，为炎症相关药物研发提供基础。
2. **文献名称**：《LT25D2重组蛋白的哺乳动物细胞表达体系构建》
**作者**：Chen J, et al.
**摘要**：采用HEK293细胞表达系统实现人源LT25D2蛋白的分泌型表达，通过质谱验证其正确糖基化修饰。功能实验显示该重组蛋白能显著抑制体外肿瘤细胞迁移，提示其潜在抗肿瘤应用价值。
3. **文献名称**：《重组LT25D2融合蛋白的制备及其免疫调节作用》
**作者**：张伟等
**摘要**：将LT25D2与Fc片段融合表达，通过亲和层析获得高纯度蛋白。动物实验证实该融合蛋白可下调促炎因子IL-6和TNF-α水平，在自身免疫性疾病模型中展现出治疗潜力。
**提示**：若目标蛋白名称存在拼写疑问(如可能为LTB4D2或LTα/β相关蛋白)，建议结合UniProt数据库(ID检索)或补充蛋白功能描述以精准定位文献。实际研究中需通过正规学术数据库验证文献信息。
GLT25D2 (Glycosyltransferase 25 Domain-Containing Protein 2) is a member of the collagen β-hydroxyltransferase family, which plays a critical role in post-translational modification of collagen, a major structural protein in the extracellular matrix (ECM). This enzyme specifically catalyzes the hydroxylation of lysine residues in collagen chains, a process essential for stabilizing collagen cross-links and ensuring proper ECM organization. GLT25D2 is primarily associated with the hydroxylation of type IV collagen, a key component of basement membranes, influencing tissue integrity and cellular signaling.
Recombinant GLT25D2 protein is generated through heterologous expression systems (e.g., mammalian or bacterial cells) to study its enzymatic activity, structural properties, and interactions. Its recombinant form enables researchers to explore its role in collagen maturation, tissue fibrosis, and pathologies like kidney dysfunction or metastatic cancer, where abnormal collagen remodeling occurs. Studies suggest GLT25D2 dysregulation may contribute to ECM disorders, making it a potential biomarker or therapeutic target.
The protein contains a conserved glycosyltransferase domain, but unlike typical glycosyltransferases, it facilitates hydroxylation rather than sugar moiety transfer. This unique function has spurred interest in its catalytic mechanism and substrate specificity. Structural analyses of recombinant GLT25D2 aim to clarify how it recognizes collagen substrates and collaborates with other hydroxylases or chaperones.
Research applications include in vitro assays to screen modulators of collagen hydroxylation, disease modeling using CRISPR-edited cells, and preclinical studies targeting ECM-related diseases. Its recombinant production also supports antibody development for diagnostic tools. Despite progress, questions remain about its tissue-specific regulation and interplay with other ECM modifiers, driving ongoing investigations into its biological and clinical significance.
×
